Haryana, India – October 21, 2021
Infosys Foundation, the philanthropic and CSR arm of Infosys (NSE, BSE, NYSE: INFY), today inaugurated the ‘Infosys Foundation Vishram Sadan’ (Dharamshala or rest house), near the National Cancer Institute, All India Institute of Medical Science (AIIMS) in Jhajjar, Haryana. The Infosys Foundation Vishram Sadan was inaugurated virtually by Honorable Prime Minister Shri. Narendra Modi.
The Infosys Foundation Vishram Sadan, a ten-storey structure has been built over an area of 271,250 sq. ft at an estimated cost of INR 93 crores. The Infosys Foundation Dharamshala will be able to accommodate close to 800 underprivileged patients and their families for both short-and long-term stays, depending on the nature of treatment.
Speaking on the occasion, Mrs. Sudha Murty, Chairperson, Infosys Foundation, said, “AIIMS is one of the most premier hospitals and medical educational institutions in India, and we are honored to be able to support this cause, in our aim to help cancer patients and their families especially the underprivileged. We thank our Hon’ble Prime Minister Shri. Narendra Modi for gracing this occasion. We would like to dedicate this facility to the needy patients in our country.”
Prof. Aarti Vij, Chairperson – Media & Protocol, AIIMS, New Delhi, said,” We thank Infosys Foundation for their unwavering support in helping those who need it. Many of our patients at AIIMS come from underprivileged backgrounds and are unable to help fund their treatment and other related expenses. The Infosys Foundation Vishram Sadan will help accommodate patients and their families free of cost. We are grateful to Infosys Foundation for coming forward and helping us out in this endeavor. “
This initiative further adds to Infosys Foundation’s efforts to expand hospital and quarantine facilities and ensure proper medical treatment for the public. The Foundation recently supported the construction of the ‘Infosys Foundation Asha Nivas’ Dharamshala at The Tata Memorial Centre, in Navi Mumbai, a 75,000 sq. ft state-of-the-art, multi-disciplinary Outpatient Department (OPD) block at the Kidwai Memorial Institute of Oncology, Bengaluru, and a Silver Jubilee medical block at the Ramakrishna Sevashrama in Pavagada, Karnataka.
Over the last one and a half years, Infosys committed a total of INR 200 Crore for Covid relief efforts across India. The Infosys Foundation also set up a 150-bed Covid care hospital in Bengaluru, in partnership with the state government.
Established in 1996, the Infosys Foundation supports programs in the areas of education, rural development, healthcare, arts and culture, and destitute care. Its mission is to work in remote regions of several states in India. The Infosys Foundation takes pride in working with all sections of society, selecting projects with infinite care, and working in areas that are traditionally overlooked by society at large. For more details, please log on: https://www.infosys.com/infosys-foundation
Infosys is a global leader in next-generation digital services and consulting. We enable clients in more than 50 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.
Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.
Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2021. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.
For more information contact: [email protected]